{"DataElement":{"publicId":"6704130","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome AJCC Edition 8 Peripheral Blood Involvement Category","preferredDefinition":"Extent of the peripheral blood involvement for mycosis fungoides and sezary syndrome using AJCC Ed. 8 criteria.","longName":"MFSS_AJC8_PBI_CAT","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"6703185","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome Peripheral Blood Involvement","preferredDefinition":"Mature T and NK neoplasms predominantly affecting the skin and the peripheral blood.  Peripheral blood involvement by abnormal T-cells (cerebriform cells) is a late manifestation of mycosis fungoides, whereas it is the presenting finding in Sezary syndrome. --2003_On or near an edge or constituting an outer boundary; the outer area._A tissue with red blood cells, white blood cells, platelets, and other substances suspended in fluid called plasma. Blood takes oxygen and nutrients to the tissues, and carries away wastes._To have a connection by participation or association or use; sharing in an activity or process.","longName":"6702710v1.0:6703183v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"6702710","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome","preferredDefinition":"Mature T and NK neoplasms predominantly affecting the skin and the peripheral blood.  Peripheral blood involvement by abnormal T-cells (cerebriform cells) is a late manifestation of mycosis fungoides, whereas it is the presenting finding in Sezary syndrome. --2003","longName":"C9265","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycosis Fungoides and Sezary Syndrome","conceptCode":"C9265","definition":"Mature T and NK neoplasms predominantly affecting the skin and the peripheral blood.  Peripheral blood involvement by abnormal T-cells (cerebriform cells) is a late manifestation of mycosis fungoides, whereas it is the presenting finding in Sezary syndrome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"86CE9C6C-F805-26F5-E053-F662850A0B07","latestVersionIndicator":"Yes","beginDate":"2019-04-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-18","modifiedBy":"ONEDATA","dateModified":"2019-04-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6703183","version":"1","preferredName":"Peripheral Blood Involvement","preferredDefinition":"On or near an edge or constituting an outer boundary; the outer area.:A liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood.:To have a connection by participation or association or use; sharing in an activity or process.","longName":"C25233:C12434:C25548","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Peripheral","conceptCode":"C25233","definition":"On or near an edge or constituting an outer boundary; the outer area.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Blood","conceptCode":"C12434","definition":"A liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Involvement","conceptCode":"C25548","definition":"To have a connection by participation or association or use; sharing in an activity or process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86D3E480-F210-0AB8-E053-F662850AFB27","latestVersionIndicator":"Yes","beginDate":"2019-04-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-18","modifiedBy":"ONEDATA","dateModified":"2019-04-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"86D3E480-F221-0AB8-E053-F662850AFB27","latestVersionIndicator":"Yes","beginDate":"2019-04-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-18","modifiedBy":"COOPERM","dateModified":"2019-04-29","changeDescription":"4-18-19 created for standardization; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6704112","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome American Joint Committee on Cancer Edition 8 Peripheral Blood Involvement Category","preferredDefinition":"A finding about one or more characteristics of mycosis fungoides and Sezary syndrome, following the rules of the TNM AJCC v8 classification system as they pertain to peripheral blood involvement._A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications._A grouping of items based on some commonality or by user defined characteristics.","longName":"6704112v1.0","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"B2","valueDescription":"Mycosis Fungoides and Sezary Syndrome B2 TNM Finding v8","ValueMeaning":{"publicId":"6704114","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome B2 TNM Finding v8","longName":"6704114","preferredDefinition":"High blood tumor burden: 1,000 per microliter or more Sezary cells with positive clone. Note 1: for blood, Sezary cells are defined as lymphocytes with hyperconvoluted cerebriform nuclei. If Sezary cells cannot be used to determine tumor burden for B2, then one of the following modified ISCL criteria along with a positive clonal rearrangement of the TCR may be used instead: (1) expanded CD4+ or CD3+ cells with CD4/CD8 ratio of 10 or more, (2) expanded CD4+ cells with abnormal immunophenotype including loss of CD7 or CD26. Note 2: A T-cell clone is defined by PCR or Southern blot analysis of the T-cell receptor gene. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycosis Fungoides and Sezary Syndrome B2 TNM Finding v8","conceptCode":"C141329","definition":"High blood tumor burden: 1,000 per microliter or more Sezary cells with positive clone. Note 1: for blood, Sezary cells are defined as lymphocytes with hyperconvoluted cerebriform nuclei. If Sezary cells cannot be used to determine tumor burden for B2, then one of the following modified ISCL criteria along with a positive clonal rearrangement of the TCR may be used instead: (1) expanded CD4+ or CD3+ cells with CD4/CD8 ratio of 10 or more, (2) expanded CD4+ cells with abnormal immunophenotype including loss of CD7 or CD26. Note 2: A T-cell clone is defined by PCR or Southern blot analysis of the T-cell receptor gene. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E28EAF-45DD-66CC-E053-F662850A19E4","latestVersionIndicator":"Yes","beginDate":"2019-04-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-19","modifiedBy":"COOPERM","dateModified":"2019-04-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86E28EAF-45F6-66CC-E053-F662850A19E4","beginDate":"2019-04-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-19","modifiedBy":"ONEDATA","dateModified":"2019-04-19","deletedIndicator":"No"},{"value":"B1b","valueDescription":"Mycosis Fungoides and Sezary Syndrome B1b TNM Finding v8","ValueMeaning":{"publicId":"6704116","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome B1b TNM Finding v8","longName":"6704116","preferredDefinition":"Clone positive. Note: A T-cell clone is defined by polymerase chain reaction (PCR) or Southern blot analysis of the TCR gene. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycosis Fungoides and Sezary Syndrome B1b TNM Finding v8","conceptCode":"C141328","definition":"Clone positive. Note: A T-cell clone is defined by polymerase chain reaction (PCR) or Southern blot analysis of the TCR gene. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E28EAF-4603-66CC-E053-F662850A19E4","latestVersionIndicator":"Yes","beginDate":"2019-04-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-19","modifiedBy":"ONEDATA","dateModified":"2019-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86E28EAF-461C-66CC-E053-F662850A19E4","beginDate":"2019-04-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-19","modifiedBy":"ONEDATA","dateModified":"2019-04-19","deletedIndicator":"No"},{"value":"B1a","valueDescription":"Mycosis Fungoides and Sezary Syndrome B1a TNM Finding v8","ValueMeaning":{"publicId":"6704118","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome B1a TNM Finding v8","longName":"6704118","preferredDefinition":"Clone negative. Note: A T-cell clone is defined by polymerase chain reaction (PCR) or Southern blot analysis of the TCR gene. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycosis Fungoides and Sezary Syndrome B1a TNM Finding v8","conceptCode":"C141327","definition":"Clone negative. Note: A T-cell clone is defined by polymerase chain reaction (PCR) or Southern blot analysis of the TCR gene. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E28EAF-4629-66CC-E053-F662850A19E4","latestVersionIndicator":"Yes","beginDate":"2019-04-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-19","modifiedBy":"ONEDATA","dateModified":"2019-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86E28EAF-4642-66CC-E053-F662850A19E4","beginDate":"2019-04-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-19","modifiedBy":"ONEDATA","dateModified":"2019-04-19","deletedIndicator":"No"},{"value":"B1","valueDescription":"Mycosis Fungoides and Sezary Syndrome B1 TNM Finding v8","ValueMeaning":{"publicId":"6704120","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome B1 TNM Finding v8","longName":"6704120","preferredDefinition":"Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary) cells but does not meet the criteria of B2. (from AJCC 7th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycosis Fungoides and Sezary Syndrome B1 TNM Finding v8","conceptCode":"C141326","definition":"Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary) cells but does not meet the criteria of B2. (from AJCC 7th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E28EAF-464F-66CC-E053-F662850A19E4","latestVersionIndicator":"Yes","beginDate":"2019-04-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-19","modifiedBy":"COOPERM","dateModified":"2019-04-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86E28EAF-4668-66CC-E053-F662850A19E4","beginDate":"2019-04-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-19","modifiedBy":"ONEDATA","dateModified":"2019-04-19","deletedIndicator":"No"},{"value":"B0b","valueDescription":"Mycosis Fungoides and Sezary Syndrome B0b TNM Finding v8","ValueMeaning":{"publicId":"6704122","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome B0b TNM Finding v8","longName":"6704122","preferredDefinition":"Clone positive. Note: A T-cell clone is defined by polymerase chain reaction (PCR) or Southern blot analysis of the TCR gene. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycosis Fungoides and Sezary Syndrome B0b TNM Finding v8","conceptCode":"C141325","definition":"Clone positive. Note: A T-cell clone is defined by polymerase chain reaction (PCR) or Southern blot analysis of the TCR gene. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E28EAF-4675-66CC-E053-F662850A19E4","latestVersionIndicator":"Yes","beginDate":"2019-04-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-19","modifiedBy":"ONEDATA","dateModified":"2019-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86E28EAF-468E-66CC-E053-F662850A19E4","beginDate":"2019-04-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-19","modifiedBy":"ONEDATA","dateModified":"2019-04-19","deletedIndicator":"No"},{"value":"B0a","valueDescription":"Mycosis Fungoides and Sezary Syndrome B0a TNM Finding v8","ValueMeaning":{"publicId":"6704124","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome B0a TNM Finding v8","longName":"6704124","preferredDefinition":"Clone negative. Note: A T-cell clone is defined by polymerase chain reaction (PCR) or Southern blot analysis of the TCR gene. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycosis Fungoides and Sezary Syndrome B0a TNM Finding v8","conceptCode":"C141324","definition":"Clone negative. Note: A T-cell clone is defined by polymerase chain reaction (PCR) or Southern blot analysis of the TCR gene. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E28EAF-469B-66CC-E053-F662850A19E4","latestVersionIndicator":"Yes","beginDate":"2019-04-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-19","modifiedBy":"ONEDATA","dateModified":"2019-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86E28EAF-46B4-66CC-E053-F662850A19E4","beginDate":"2019-04-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-19","modifiedBy":"ONEDATA","dateModified":"2019-04-19","deletedIndicator":"No"},{"value":"B0","valueDescription":"Mycosis Fungoides and Sezary Syndrome B0 TNM Finding v8","ValueMeaning":{"publicId":"6704126","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome B0 TNM Finding v8","longName":"6704126","preferredDefinition":"Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). Note: for blood, Sezary cells are defined as lymphocytes with hyperconvoluted cerebriform nuclei. If Sezary cells cannot be used to determine tumor burden for B2, then one of the following modified ISCL criteria along with a positive clonal rearrangement of the TCR may be used instead: (1) expanded CD4+ or CD3+ cells with CD4/CD8 ratio of 10 or more, (2) expanded CD4+ cells with abnormal immunophenotype including loss of CD7 or CD26. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycosis Fungoides and Sezary Syndrome B0 TNM Finding v8","conceptCode":"C141323","definition":"Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). Note: for blood, Sezary cells are defined as lymphocytes with hyperconvoluted cerebriform nuclei. If Sezary cells cannot be used to determine tumor burden for B2, then one of the following modified ISCL criteria along with a positive clonal rearrangement of the TCR may be used instead: (1) expanded CD4+ or CD3+ cells with CD4/CD8 ratio of 10 or more, (2) expanded CD4+ cells with abnormal immunophenotype including loss of CD7 or CD26. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E28EAF-46C1-66CC-E053-F662850A19E4","latestVersionIndicator":"Yes","beginDate":"2019-04-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-19","modifiedBy":"ONEDATA","dateModified":"2019-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86E28EAF-46DA-66CC-E053-F662850A19E4","beginDate":"2019-04-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-19","modifiedBy":"ONEDATA","dateModified":"2019-04-19","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6704111","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome Peripheral Blood Involvement TNM Finding v8 American Joint Committee on Cancer Category","preferredDefinition":"A finding about one or more characteristics of mycosis fungoides and Sezary syndrome, following the rules of the TNM AJCC v8 classification system as they pertain to peripheral blood involvement.:A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.:A grouping of items based on some commonality or by user defined characteristics.","longName":"C141322:C39315:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycosis Fungoides and Sezary Syndrome Peripheral Blood Involvement TNM Finding v8","conceptCode":"C141322","definition":"A finding about one or more characteristics of mycosis fungoides and Sezary syndrome, following the rules of the TNM AJCC v8 classification system as they pertain to peripheral blood involvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"American Joint Committee on Cancer","conceptCode":"C39315","definition":"A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E28EAF-45B0-66CC-E053-F662850A19E4","latestVersionIndicator":"Yes","beginDate":"2019-04-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-19","modifiedBy":"ONEDATA","dateModified":"2019-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"86E28EAF-45C1-66CC-E053-F662850A19E4","latestVersionIndicator":"Yes","beginDate":"2019-04-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-19","modifiedBy":"COOPERM","dateModified":"2019-04-29","changeDescription":"4-19-19 created for standardization; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"5574838","version":"1","longName":"Staging/Extent of Disease","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"6005920","version":"1","longName":"AJCC Edition 8","context":"NCI Standards"},{"publicId":"6702791","version":"1","longName":"Mycosis Fungoides and Sezary Syndrome","context":"NCI Standards"}]}],"AlternateNames":[{"name":"CCR","type":"USED_BY","context":"CCR"}],"ReferenceDocuments":[{"name":"CCR Document Text","type":"Alternate Question Text","description":"Blood","url":null,"context":"CCR"},{"name":"Peripheral blood involvement","type":"Preferred Question Text","description":"Peripheral blood involvement","url":null,"context":"NCI Standards"}],"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"86E2E0C4-5445-641B-E053-F662850AC5BD","latestVersionIndicator":"Yes","beginDate":"2019-04-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-19","modifiedBy":"COOPERM","dateModified":"2019-04-29","changeDescription":"4-19-19 created for standardization; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}